19 results about "Tissue selectivity" patented technology

The invention concerns a novel microassay device comprising a plurality of pillars functionalised using antibody specific for the isolation of extracellular vesicles (EVs), typically but not exclusively from human blood or cell culture media, and including electrodes for measuring impedance; wherein said pillars are made from, or coated with, a copolymer comprising, as copolymerized units, at least one polythiol monomer ('thiol monomer') and at least one polyalkene / alkyne monomer ('ene' monomer'), wherein the ratio of thiol to alkene / alkyne functional groups in said copolymer has an excess of alkene / alkyne functional groups, optionally from about 100:150 to 100:105; a method for the fabrication of said device; use of the device for tissue-selective isolation of EVs, and / or quantifying the amount of said EVs, and / or assaying the enzyme activity of said EVs, such as that of Cytochrome P450 enzymes or UDP-glucuronosyl transferases or, indeed, any other enzyme(s) contained in the cells or EVs; and a kit of parts including said device.

The invention discloses a nano-drug delivery system for treating myocardial fibrosis as well as a preparation method and application of the nano-drug delivery system, and belongs to the technical field of biological medicines. According to the system, ZIF-8 is taken as a core carrier, the loading efficiency of pirfenidone is improved through high specific surface area and adjustable aperture, PCM myocardial targeting peptide is covalently coupled on the surface, and the limitation of tissue selectivity is broken through. Through coordination complexation, pi-pi conjugate accumulation and electrostatic interaction synergy, stable drug loading and microenvironment response release are guaranteed; a one-pot method and a carbodiimide method are adopted to wrap PFD and modify PCM on the surface of ZIF-8 to form a nano-drug delivery system; according to the system, the fibrosis process is intervened through multiple mechanisms, the enrichment degree and the acting time of the medicine at the diseased region are improved, the prepared medicine integrates the carrier structure advantage and the targeting peptide function, efficient medicine carrying, precise delivery and controllable release are achieved, a new scheme is provided for myocardial fibrosis treatment, and the system has wide application prospects.

The present application is related to a tissue-selective single-component mRNA delivery carrier and a delivery system. Poly (β-amino ester) polymer is used as the single-component delivery carrier, wherein the poly (β-amino ester) polymer has a structure as shown in Formula I or Formula II. In Formula I or Formula II, the definition of each substituents is the same as in the detailed description. The present invention employs only the poly(β-amino ester) polymer material as the single delivery carrier, and tissue-selective targeting of the delivery system including lung, liver and spleen, etc. can be achieved by locally regulating the chemical structures and the domain charges of the poly(β-amino ester) polymer.

The present invention relates to hybrid transcriptional regulatory elements driving gene expression, in particular hybrid promoters, which are designed by fusing at least two transcriptional regulatory elements with different tissue selectivities, such as two promoters that drive expression in different tissues in a tissue-selective manner.

The invention provides an ablation device and a prostate tissue ablation system.The ablation tissue comprises a head electrode assembly, a needle electrode assembly and a handle assembly, the head electrode assembly comprises a head end main body and an outer tube which are connected with each other, the head end main body is arranged at the far end of the outer tube, a head electrode is arranged at the far end of the head end main body, and the needle electrode assembly is arranged on the outer tube. A needle electrode channel is arranged in the outer tube, the needle electrode assembly is contained in the needle electrode channel, the needle electrode assembly comprises at least one needle electrode, and the needle electrode assembly extends out of the side face of the ablation device based on operation on the handle assembly. According to the embodiment of the invention, the interventional operation of entering the urethra through a natural orifice and operating under a visual working condition and adopting an irreversible electroporation steep pulse electric field with tissue selectivity can be realized, so that the operation efficiency and the operation safety and effectiveness are greatly improved.

Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR / Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the triggerbinding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently. Disclosed herein are allosteric cgRNA mechanisms for both ON→OFF logic (conditional inactivation by an RNA trigger) and OFF→ON logic (conditional activation by an RNA trigger). Allosteric cgRNAs enable restriction of CRISPR / Cas function to a desired cell type, tissue, organ, or disease state. Allosteric cgRNAs provide a versatile platform for cell-selective and tissue-selective research tools, biotechnologies, diagnostics, and therapeutics.

This invention provides a medical repair membrane with an orthogonal crack-limiting structure and its preparation method. This invention relates to the field of biomedical materials technology. The medical repair membrane of this invention comprises at least two electrospun fiber layers, which intersect to form an orthogonal fiber structure. Layer B, facing tissue integration, adopts a coaxial core-shell structure. The shell layer contains biodegradable polymers and bioactive components, while the core layer is a biodegradable polymer. The structure of this invention effectively inhibits crack propagation and improves the structural stability of the material. Simultaneously, the core-shell structure enables controlled release of active components and tissue-selective induction, balancing mechanical properties and biocompatibility. The medical repair membrane is suitable for soft tissue defect repair, such as dura mater repair, fascia repair, pericardial repair, and hernia repair.

A medical water jet scalpel device (100) and a medical water jet scalpel system are disclosed. The medical water jet scalpel system comprises the medical water jet scalpel device (100). The medical water jet scalpel device (100) comprises an outer tube (110), a jet tube (120), a nozzle (130) and a driving apparatus (140). The jet tube (120) extends through the outer tube (110) and is configured to input medical liquid. A gap is formed between an outer wall of the jet tube (120) and an inner wall of the outer pipe (110). The nozzle (130) is arranged at a distal end of the jet tube (120) and is configured to output the medical liquid. The driving apparatus (140) is connected to at least part of the jet tube (120) and is configured to drive the distal end of the jet tube (120) to swing back and forth or rotate around the central axis of the outer tube (110). The medical water jet scalpel device (100) automatically drives, by means of the driving apparatus (140), the jet tube (120) limited in the outer tube (110) to move, such that the nozzle (130) of the medical water jet scalpel device (100) performs a rapid scanning motion to replace rapid shaking of a surgeon when manually operating the medical water jet scalpel device (100), thereby greatly reducing the operation difficulty, increasing the efficiency of a surgical operation for selective separation by a water jet scalpel, and improving the effect of tissue selective separation and the surgical operation accuracy.

A phosphor excitable by X-ray and blue-light emits light in the near-infrared (NIR-II, 1000-1700 nanometers) forms nanoparticles less than 200 nanometers diameter. The nanoparticles are tagged by coating with silica, then conjugating with polyethylene glycol (PEG) and tissue-selective compounds such as antibodies, nucleic acid chains, and other ligands. In embodiments, we administer the tagged nanoparticles to a subject, then localize the nanoparticles, and thus antigen-bearing tissues, by irradiating the subject with X-ray or other radiation beams while imaging near infrared light emitted from the subject. The nanoparticles are made by mixing 1-50 micron calcium oxide and germanium oxide powders with dilute nitric acid, adding chromium (III) nitrate at a ratio to germanium between 0.001 and 0.1, adding tartaric acid solution with molar ratio to metal ions between 1˜10, and adjusting pH to 0.1-4 with nitric acid, then later heating to form a sol, oven drying, and calcinating the sol.

Disclosed in the present invention are a heteroaromatic amine compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound of the present invention has one or more of the following advantages: (1) excellent agonistic activity on 5-hydroxytryptamine 4 receptor; (2) good selective agonistic activity on 5-hydroxytryptamine 4 receptor; (3) capability of significantly reducing the risk of cardiotoxicity caused by hERG channel suppression; and (4) excellent intestinal tissue selectivity and low system exposure, which can reduce the safety risk of the circulatory system.

This invention discloses a photoproduce molecule targeting the PD-L1 immune checkpoint, its preparation method, and its application. Addressing the lack of tissue selectivity in existing PD-L1 small molecule inhibitors, this invention provides a photoproduce molecule as shown in general formula (I) or a pharmaceutically acceptable salt thereof, which covalently links a PD-L1 inhibitor to coumarin via a cleavable linker bond. This photoproduce can be rapidly activated (<10 min) under ultraviolet light, simultaneously releasing the fluorophore and the parent drug, achieving spatiotemporally controllable release of PD-L1 inhibitor activity. This invention also provides a synthesis method and its application in photoimmunotherapy.

Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR / Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger-binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently. Disclosed herein are allosteric cgRNA mechanisms for both ON→OFF logic (conditional inactivation by an RNA trigger) and OFF→ON logic (conditional activation by an RNA trigger). Allosteric cgRNAs enable restriction of CRISPR / Cas function to a desired cell type, tissue, organ, or disease state. Allosteric cgRNAs provide a versatile platform for cell-selective and tissue-selective research tools, biotechnologies, diagnostics, and therapeutics.

An aspect of the present invention provides tissue-selective delivery of thyroid hormone receptor (TR)β agonists or antagonists using particle delivery systems. Specifically, aspects of the invention provide pharmaceutical compositions comprising effective amounts of a TRβ agonist or antagonist encapsulated in a particle carrier, as well as methods for using the same to treat various medical diseases and conditions. In various embodiments, the compositions mediate selective TRβ activation in a tissue selective manner.

The invention relates to heterozygous regulatory elements. Specifically, the present invention relates to hybrid transcriptional regulatory elements, in particular hybrid promoters, that drive gene expression, designed by fusion of at least two transcriptional regulatory elements having different tissue selectivity, for example two promoters that drive expression in different tissues in a tissue-selective manner.

The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner.

A phosphor excitable by X-ray and blue-light emits light in the near-infrared (NIR-II, 1000-1700 nanometers) forms nanoparticles less than 200 nanometers diameter. The nanoparticles are tagged by coating with silica, then conjugating with polyethylene glycol (PEG) and tissue-selective compounds such as antibodies, nucleic acid chains, and other ligands. In embodiments, we administer the tagged nanoparticles to a subject, then localize the nanoparticles, and thus antigen-bearing tissues, by irradiating the subject with X-ray or other radiation beams while imaging near infrared light emitted from the subject. The nanoparticles are made by mixing 1-50 micron calcium oxide and germanium oxide powders with dilute nitric acid, adding chromium (III) nitrate at a ratio to germanium between 0.001 and 0.1, adding tartaric acid solution with molar ratio to metal ions between 1˜10, and adjusting pH to 0.1-4 with nitric acid, then later heating to form a sol, oven drying, and calcinating the sol.

Some implementations provide a high-powered compact ultrasonic transducer having an integral piezoelectric ceramic force sensing element utilized to enable enhanced tissue selectivity with a piezoelectric based transducer. Some implementations additionally or alternatively relate to methods and apparatus for driving ultrasonic surgical devices, such as methods and apparatus that modulate an amplitude of a drive signal, provided to an ultrasonic surgical device, in accordance with a selected tissue selectivity level. For example, the amplitude of the drive signal for a given tissue selectivity level can be varied with time in accordance with amplitude modification parameters that are particularized to the given tissue selectivity level. Some of those implementations additionally implement a corresponding duty cycle, for the drive signal, that corresponds to the selected tissue selectivity level.

The invention refers to modified carbohydrate-responsive element-binding proteins (ChREBP's) functional as tissue specific antagonist and / or agonist for use in medicine.

In some embodiments, the instant invention includes a laser device that includes: a laser generating module that produces a plurality of laser pulses having a time-stricture pulse format that includes at least: a plurality of micropulses, a macropulse time envelope, where the plurality of micropulses are within the macropulse time envelope; where the time-stricture pulse format is configured so that the laser device is capable of treating human tissue by selectively targeting or affecting at least one first tissue or at least one first disease organisms while not substantially affecting at least one first surrounding or adjacent tissue.